Copyright Reports & Markets. All rights reserved.

Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Valsartan
      • 1.4.3 Irbesartan
      • 1.4.4 Candesartan Cilexetil
      • 1.4.5 Eprosartan
      • 1.4.6 Irbesartan
      • 1.4.7 Telmisartan
      • 1.4.8 losartan
      • 1.4.9 Olmesartan Medoxomil
      • 1.4.10 Allisartan isoproxil
    • 1.5 Market by Application
      • 1.5.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2014-2025)
      • 1.5.2 High Blood Pressure
      • 1.5.3 Congestive Heart Failure
      • 1.5.4 Left Ventricular Hypertrophy
      • 1.5.5 Atherosclerosis
      • 1.5.6 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size
    • 2.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Growth Trends by Regions
      • 2.2.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Regions (2014-2025)
      • 2.2.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by by Players
      • 3.1.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by by Players (2014-2019)
      • 3.1.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Concentration Ratio (CR5 and HHI)
    • 3.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players Head office and Area Served
    • 3.3 Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product/Solution/Service
    • 3.4 Date of Enter into Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2014-2019)
    • 4.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2014-2019)
    • 5.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in United States
    • 5.3 United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type
    • 5.4 United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application

    6 Europe

    • 6.1 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2014-2019)
    • 6.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Europe
    • 6.3 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type
    • 6.4 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application

    7 China

    • 7.1 China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2014-2019)
    • 7.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in China
    • 7.3 China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type
    • 7.4 China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application

    8 Japan

    • 8.1 Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2014-2019)
    • 8.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Japan
    • 8.3 Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type
    • 8.4 Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2014-2019)
    • 9.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Southeast Asia
    • 9.3 Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type
    • 9.4 Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application

    10 India

    • 10.1 India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2014-2019)
    • 10.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in India
    • 10.3 India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type
    • 10.4 India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2014-2019)
    • 11.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Central & South America
    • 11.3 Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type
    • 11.4 Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application

    12 International Players Profiles

    • 12.1 Pfizer
      • 12.1.1 Pfizer Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
      • 12.1.4 Pfizer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2014-2019)
      • 12.1.5 Pfizer Recent Development
    • 12.2 Novartis
      • 12.2.1 Novartis Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
      • 12.2.4 Novartis Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2014-2019)
      • 12.2.5 Novartis Recent Development
    • 12.3 Merck
      • 12.3.1 Merck Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
      • 12.3.4 Merck Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2014-2019)
      • 12.3.5 Merck Recent Development
    • 12.4 AstraZeneca
      • 12.4.1 AstraZeneca Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
      • 12.4.4 AstraZeneca Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2014-2019)
      • 12.4.5 AstraZeneca Recent Development
    • 12.5 Jhonson and Johnson
      • 12.5.1 Jhonson and Johnson Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
      • 12.5.4 Jhonson and Johnson Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2014-2019)
      • 12.5.5 Jhonson and Johnson Recent Development
    • 12.6 Eli Lilly
      • 12.6.1 Eli Lilly Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
      • 12.6.4 Eli Lilly Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2014-2019)
      • 12.6.5 Eli Lilly Recent Development
    • 12.7 Sanofi
      • 12.7.1 Sanofi Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
      • 12.7.4 Sanofi Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2014-2019)
      • 12.7.5 Sanofi Recent Development
    • 12.8 Bristol-Myers Squibb
      • 12.8.1 Bristol-Myers Squibb Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
      • 12.8.4 Bristol-Myers Squibb Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2014-2019)
      • 12.8.5 Bristol-Myers Squibb Recent Development
    • 12.9 Bayer
      • 12.9.1 Bayer Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
      • 12.9.4 Bayer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2014-2019)
      • 12.9.5 Bayer Recent Development
    • 12.10 GSK
      • 12.10.1 GSK Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
      • 12.10.4 GSK Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2014-2019)
      • 12.10.5 GSK Recent Development
    • 12.11 Teva Pharmaceutical
    • 12.12 Shenzhen Salubris Pharmaceuticals
    • 12.13 Sun Pharmaceutical
    • 12.14 Mylan
    • 12.15 Alembic Pharmaceuticals
    • 12.16 Lupin
    • 12.17 Aurobindo Pharma
    • 12.18 Amneal Pharmaceuticals
    • 12.19 Boehringer Ingelheim

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      In 2018, the global Non-Peptide Drugs of Angiotensin II Receptor Antagonist market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Non-Peptide Drugs of Angiotensin II Receptor Antagonist status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Non-Peptide Drugs of Angiotensin II Receptor Antagonist development in United States, Europe and China.

      The key players covered in this study
      Pfizer
      Novartis
      Merck
      AstraZeneca
      Jhonson and Johnson
      Eli Lilly
      Sanofi
      Bristol-Myers Squibb
      Bayer
      GSK
      Teva Pharmaceutical
      Shenzhen Salubris Pharmaceuticals 
      Sun Pharmaceutical
      Mylan
      Alembic Pharmaceuticals
      Lupin
      Aurobindo Pharma
      Amneal Pharmaceuticals
      Boehringer Ingelheim

      Market segment by Type, the product can be split into
      Valsartan
      Irbesartan
      Candesartan Cilexetil
      Eprosartan
      Irbesartan
      Telmisartan
      losartan
      Olmesartan Medoxomil
      Allisartan isoproxil

      Market segment by Application, split into
      High Blood Pressure
      Congestive Heart Failure
      Left Ventricular Hypertrophy
      Atherosclerosis
      Other

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Non-Peptide Drugs of Angiotensin II Receptor Antagonist status, future forecast, growth opportunity, key market and key players.
      To present the Non-Peptide Drugs of Angiotensin II Receptor Antagonist development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Non-Peptide Drugs of Angiotensin II Receptor Antagonist are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now